Astellas and Pfizer outline insights planned for 2024 ASCO meeting

13 May 2024

Oncology companies including New York-based giant Pfizer (NYSE: PFE) and Japan’s Astellas Pharma (TYO: 4503) have outlined details of data they intend to present at the USA’s leading cancer conference.

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago from 31 May to 4 June, with more than 5,000 abstracts due to be presented or published during the event.

Smaller companies to provide a preview include Californian firms Calidi Biotherapeutics (NYSE American: CLDI) and A2 Biotherapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK